(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Overactive Bladder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
- Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
- Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
- Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
- In March 2023, MSN Laboratories released Fesobig, the generic alternative to Fesoterodine Fumarate, which serves as a primary pharmacological choice for managing Overactive Bladder (OAB) symptoms.
- In January 2023, Alembic Pharmaceuticals Limited obtained approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) concerning Fesoterodine Fumarate tablets, intended for the treatment of Overactive Bladder (OAB) in adults.
- In September 2022, Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., has been honored with the prestigious Best in Category award for an interim 12-week analysis derived from the continuous Phase IIa trial of their innovative investigational gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel).
- In May 2022, Dong-A ST has commenced a comprehensive therapeutic confirmatory clinical trial. This trial is multicenter, double-blind, and includes both placebo and active-reference groups in a randomized, parallel setup. Its primary aim is to assess the safety and effectiveness of da-8010 in patients diagnosed with overactive bladder.
- For OAB patients who have not responded to oral pharmaceutical treatment, a novel gene therapy called URO-902 is being developed. Calcium-activated potassium channel opener URO902 has been shown to have a statistically significant and clinically important effect on a number of outcome variables in OAB, such as the number of urgency episodes, micturitions, and quality of life markers. For individuals with OAB, URO902 may be the first gene therapy.
Overactive Bladder Overview
The term “overactive bladder” (OAB) refers to a collection of urine symptoms. It’s not an illness. The most typical sign is an abrupt, involuntary desire or urge to urinate. OAB is defined as a condition with characteristic symptoms of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology,” as revised by the International Continence Society in 2010.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
- ARD-380: Aardvark Therapeutics
- URB937: Exxel Pharma
- Botulax: Hugel
- IMB-115: Imbrium Therapeutics
- TAC-302: Taiho Pharmaceutical
- URO-902: Sumitovant Biopharma
- DA-8010: Dong-A ST
Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
- Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
- Overactive Bladder Assessment by Product Type
- Overactive Bladder By Stage and Product Type
- Overactive Bladder Assessment by Route of Administration
- Overactive Bladder By Stage and Route of Administration
- Overactive Bladder Assessment by Molecule Type
- Overactive Bladder by Stage and Molecule Type
DelveInsight’s Overactive Bladder Report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are – Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
- Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
Overactive Bladder Pipeline Market Drivers
- Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
- However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
- Coverage: Global
- Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
- Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
- Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
- Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States